CD274 and cancer: One interesting strategy to overcome immune suppression and generate a more robust antitumor immune response is to combine cancer cell specific CAR constructs and monoclonal antibodies that disrupt checkpoint inhibition (e.g., anti-PD1, anti-PD-L1, anti-TIM-3, anti-LAG-3 antibodies) (65).